{"prompt": "['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'Study Schedule of Assessments and Procedures', 'Screening', 'Safety and Efficacy Evaluation Period', 'Perioda,', '(Continued until complete clearance)', 'Up to', 'End of', '14 days', 'Treatment 4:', 'Study:', 'before', 'Treatment 1:', 'Treatment 2:', 'Treatment 3:', 'Day 63:', 'Day 84:', 'Activities', 'Day 1', 'Day 1b', 'Day 21b', 'Day 42b', 'EOT', 'EOS', 'Informed Consent and Authorization', 'X', 'Inclusion/Exclusion Criteriad', 'X', 'X', 'Demographics', 'X', 'Height/Weight', 'X', 'X', 'Prior Relevant Medical History', 'X', '(5 years)', 'Molluscum History', 'X', 'X', 'Prior and Concomitant Medications', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital Signs (T,P)', 'f', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical Examg', 'X', 'X', 'X', 'Dermatologic Exam/lesion counth', 'X', 'X', 'X', 'X', 'X', 'X', 'LSR Assessment', 'X', 'X', 'X', 'X', 'X', 'CDLQI Assessment', 'X', 'X', 'X', 'X', 'X', 'X', 'Urine Pregnancy Testk', 'X', 'X', 'X', 'X', 'X', 'Photographs', 'X', 'X', 'X', 'X', 'X', 'Study Drug Application\"', 'X', 'X', 'X', 'X', 'PERIT Assessment & photos\"', 'X', 'X', 'X', 'X', 'Adverse Events', 'X', 'X', 'X', 'X', 'X', 'Safety Monitoring Questionnaire', 'X', 'X', 'X', 'X', 'Exposure Group Blood Draws\u00b0', 'X', 'Patient Take Home InstructionsP', 'X', 'X', 'X', 'X', 'Applicator Assessment', 'X', 'X', 'X', 'X', \"CDLQI: children's dermatology life quality index; EOS = end of study; EOT = end of treatment; LSR = local skin\", 'reaction; PERIT: patient evaluation of response to treatment; T,P= temperature, pulse', 'a.', 'Screening can occur up to 14 days prior to Study drug application on Day 1. Screening can occur on the same day as', 'treatment Day 1/Study drug application. An IRB-approved ICF must be signed before any study specific procedures', 'are performed.', 'b.', 'Subjects may be scheduled 21+/- 4 days after treatment in the event of scheduling conflict. If possible the next treatment', \"or study visit should be scheduled 21 days from the day of the subject's last study visit. The 24 hour follow-up may be\", 'conducted at +/- 3 hours. Study medication should be removed after the 24 hour draw is completed.', 'c.', 'At end of the study (EOS, ~ Day 84), all subjects with unresolved molluscum lesions or unresolved treatment-emergent', 'AEs, will be treated by the investigator per local standard of care. Patients who clear all lesions at study visits prior to', '~Day 84 will complete all study related assessments that were required at the EOS visit and will not need to return for', 'further assessment. A study completion form will be completed on the day they are cleared.', 'd.', 'Confirmation of eligibility criteria.', 'e.', 'Demographics: date of birth, sex, race/ethnicity will be collected.', 'f.', 'Vital signs (e.g., temperature & heart rate) will be obtained at screening and at each treatment prior to application of', 'Study drug.', 'g. Limited physical examination. Symptom- or AE-directed physical examination may be performed if warranted. (See', 'Source/CRF for further outline of assessment.)', 'h. Regional lesion counts (head/neck, trunk, upper/lower extremities) should be performed.', 'i.', 'LSR assessment will be performed by the Investigator or trained personnel with a protocol-specific LSR form at each', 'treatment visit and the EOS visit.', 'j.', 'CDLQI assessment to be completed prior to Study drug application and at EOS visit. CDLQI must be repeated if the', 'first treatment is not completed within 7 days.', 'k.', 'To be performed prior to Study drug application and at EOS in any females of childbearing potential (females that are', 'capable of menstruating).', 'Page 10']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', '1.', 'Photography of molluscum lesions will occur at selected clinical sites only.', 'm. Study drug may be gently removed from individual lesions prior to 16 hours of application in the event of significant', 'blistering, significant pain or treatment emergent AEs. Study drug should not be removed from the remaining', 'unproblematic lesions until the 24 hour time point is reached. Every effort should be made to complete the PERIT at', '24 hours after application.', 'n.', 'PERIT assessment and photos are to be completed by parent/guardian at approximately 24 hours post application of', 'Study drug. Treatment may be removed prior to overnight application in the event of significant blistering, significant', 'pain or if treatment emergent AEs are experienced; however, every effort should be made to complete the PERIT at', '24 hours.', 'o.', 'Blood samples will be obtained from subjects participating in the exposure group only. Samples will be obtained at 2,', '6 and 24 hours post application of study medication. Subjects will return to the clinic at 24 hours for assessment and', 'completion of the PERIT. (See protocol to confirm study windows.)', 'p.', 'Subjects will be given take home instructions describing the normal local skin reactions and what to expect over the', 'next 24 hours to several months. A 24-hour emergency number will also be provided. The next visit date and time is', 'also indicated on the form. Polysporin will be dispensed with take home instructions for use as needed.', 'q.', 'Research staff will complete an assessment of how the applicator performed after each subject is treated.', 'Page 11']\n\n###\n\n", "completion": "END"}